Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

Sebastiano Buti¹
Alessandro Leonetti¹
Alice Dallatomasina²
Melissa Bersanelli¹

¹Medical Oncology Unit, University Hospital of Parma, Parma, ²Division of Experimental Oncology, San Raffaele Scientific Institute, Milan, Italy

Introduction: Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, and its pathogenesis is strictly related to altered cellular response to hypoxia, in which mTOR signaling pathway is implicated. Everolimus, an mTOR serine/threonine kinase inhibitor, represents a therapeutic option for the treatment of advanced RCC.

Aim: The objective of this article is to review the evidence for the treatment of metastatic RCC with everolimus.

Evidence review: Everolimus was approved for second- and third-line therapy in patients with advanced RCC according to the results of a Phase III pivotal trial that demonstrated a benefit in median progression-free survival of ~2 months compared to placebo after failure of previous lines of therapy, of which at least one was an anti-VEGFR tyrosine kinase inhibitor (TKI). The role of this drug in first-line setting has been investigated in Phase II trials, with no significant clinical benefit, even in combination with bevacizumab. Everolimus activity in non-clear cell RCC is supported by two randomized Phase II trials that confirmed the benefit in second-line setting but not in first line. Recently, two randomized Phase III trials (METEOR and CheckMate 025) demonstrated the inferiority of everolimus in second-line setting compared to the TKI caboantinib and to the immune checkpoint inhibitor nivolumab, respectively. Moreover, a recent Phase II study demonstrated a significant benefit for the second-line combination treatment with everolimus plus lenvatinib (a novel TKI) in terms of progression-free survival and overall survival compared to the single-agent everolimus. Basing on preclinical data, the main downstream effectors of mTOR cascade, S6RP and its phosphorylated form, could be good predictive biomarkers of response to everolimus. The safety profile of the drug is favorable, with a good cost-effectiveness compared to second-line sorafenib or axitinib, and no significant impact on the quality of life of treated patients has been found.

Conclusion: Everolimus still represents a current standard of treatment for RCC progressive to previous treatment lines with VEGFR-TKI. The evidence about two new molecules, caboantinib and nivolumab, successfully tested head-to-head with everolimus in recently published Phase III trials, will determine the shift of everolimus to the third-line setting and subsequent lines of treatment.

Keywords: everolimus, afinitor, evidence-based review, renal cell carcinoma, RCC

Core evidence clinical impact summary for everolimus

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Evidence</th>
<th>Implications</th>
</tr>
</thead>
</table>
| Disease-oriented evidence | Clear cell renal cell carcinoma | Clinical trials | Everolimus consistently demonstrated efficacy in the treatment of metastatic clear cell renal cell carcinoma after previous VEGFR-tyrosine kinase inhibitor failure; therefore, it is a standard of care in second- or third-line therapy. In second-line setting, it might be (Continued)
Introduction

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, and it could occur as a sporadic or hereditary malignancy; clear cell RCC (ccRCC) is the most frequent subtype of sporadic RCC (70%–85%), while other variants include papillary RCC (pRCC; 7%–15%) and chromophobe RCC (chRCC; 5%–10%).

The pathogenesis of ccRCC is mainly related to two molecular events: loss of function of VHL gene and overexpression of the HIF. The protein encoded by VHL gene is appointed to degrade oxygen-regulated subunit of HIF-1α, a protein that dimerizes with constitutively expressed HIF-1β to form a heterodimeric transcriptional factor that regulates cellular response to hypoxia. Once dimerized, HIF induces the transcription of VEGF, PDGF, and TGF-β.

The reduced activity of VHL gene results in constitutive expression of HIF-1α protein, thereby activating the hypoxic response even in the absence of a hypoxic signal, such as neoangiogenesis. The deregulation of cell homeostasis pathway is critical in ccRCC development. However, loss of VHL function alone is not sufficient for ccRCC initiation, and a higher number of genetic or epigenetic events are required.

More recently, several studies suggest the implication of mTOR signaling pathway in the growth of RCC.

The VHL/HIF and PI3K/AKT/mTOR pathways are involved in a large cross talk, contributing to ccRCC development. As already mentioned, HIF upregulation due to VHL loss of function promotes the expression of a variety of growth factors, including PDGF and VEGF. The overexpressed growth factors may activate the PI3K/AKT/mTOR pathway through tyrosine kinase receptors, with a subsequent activation of mTOR that promotes HIF expression, therefore triggering a positive feedback loop. We propose a discussion of this pathway to better understand carcinogenesis, mechanism of action, and therapeutic implications of the targeted drug everolimus.

Mechanism of action

PI3K/AKT/mTOR pathway

The PI3K/AKT/mTOR is an intracellular signaling pathway involved in various cellular activities resulting in cell proliferation and survival, differentiation, chemotaxis, molecular trafficking, and glucose homeostasis. The implication of this pathway in cancer development and diabetes has been widely investigated. Its deregulation may lead to anchorage-independent growth, increased proliferative potential, increased cell motility, metastasis, and evasion from apoptosis (Figure 1).

PI3K is an intracellular transducer enzyme that phosphorylates the membrane PIP2 to generate PIP3. PI3K can be directly activated by G protein-coupled receptors and tyrosine kinase receptors, or indirectly through the Ras-ERK pathway. Downstream, PIP3 regulates the membrane migration and activation of PDK1 that sequentially activates AKT, also known as PKB, an intracellular serine/threonine kinase. Activated AKT can bind and regulate many downstream effectors via its kinase activity: it phosphorylates and inhibits TSC, preventing the inhibition of mTOR. PI3K signaling is inhibited by the action of the PTEN that dephosphorylates PIP3, resulting in a reduced AKT activity.
mTOR is a serine/threonine protein kinase involved in the regulation of various cellular functions such as growth, proliferation, and survival. It has been shown that mTOR takes part in the formation of two distinct multiprotein complexes: 1) mTORC1, in which mTOR is complexed with regulatory-associated protein of mTOR (Raptor), and 2) mTORC2, comprising a protein called “rapamycin-insensitive companion of mTOR” (Rictor).19,20

mTORC1 promotes mRNA translation through phosphorylation of two translation regulators: 4EBP1 and S6K1/ p70S6K.21 Once phosphorylated, 4EBP1 is released from eIF4E that can interact with eIF4G and eIF4A, assembling the mammalian ribosome initiation complex at the 5′ end of an mRNA. Furthermore, the activated S6K1 (p-S6K1) phosphorylates the 40S S6RP, and this leads to increased translation of mRNAs.16

The result of the activation of mTORC1 downstream targets is the increased synthesis of proteins involved in the regulation of cell growth and survival, such as HIF-1α, FGF, VEGF, STAT3, cyclin-D, and c-Myc.22–24

The function of mTORC2 is not completely understood, but it is known to be associated with cytoskeleton organization and cell metabolism.21,24 Unlike mTORC1, mTORC2 is relatively insensitive to rapamycin, a natural antifungal antibiotic first discovered in the 1970s.24,25 Moreover, it increases the translation of HIF-2α, a type of hypoxia-inducible factor more strongly implicated in RCC tumorigenesis, not regulated by mTORC1. Whereas HIF-1α expression depends upon both mTORC1 and mTORC2, HIF-2α is just under mTORC2 control.26 Raval et al examined the transcriptional selectivity of the HIF-1α and HIF-2α isoforms in VHL-defective RCC cells in vitro. This study showed unexpected suppressive interactions among the two isoforms, with enhanced expression of HIF-2α suppressing HIF-1α and vice versa, demonstrating that HIF-1α and HIF-2α have conflicting properties in the biology of RCC. In particular in a xenograft model, HIF-1α was shown to delay tumor growth by stimulating the transcription of the prosapoptotic gene encoding BNIP3, whereas HIF-2α enhanced tumor growth through protumorigenic genes encoding cyclin-D1, TGF-α, and VEGF. Since the study demonstrated suppressive interactions between the two isoforms of HIF, it was not clear if suppression of tumor growth by HIF-1α arose from direct effects, indirect effects...
due to downregulation of HIF-2α, or a combination of both possibilities.27

mTORC2 is also involved in a positive feedback loop in PI3K/AKT pathway, since it phosphorylates the serine/threonine protein kinase AKT, one of the main upstream regulators of the signaling pathway itself.28

PI3K/AKT/mTOR pathway plays a central role in RCC tumorigenesis. Various components of this signaling cascade have been found to be overexpressed compared to normal kidneys and possibly constitutively activated in ccRCC and also in other histological subtypes.29 Expression of p-AKT, p-mTOR, and p-70S6K (isoform of S6K1) was seen in nearly 100% of both primary and metastatic RCCs (mRCCs) by immunohistochemistry, and increased proteins levels were seen in 128 primary RCCs, 22 mRCCs, and 24 normal kidneys.30 Immunohistochemical analyses were also conducted on 375 patients treated with nephrectomy for RCC; p-AKT and p-70S6K were detected in a high percentage of cases (40% and 75%, respectively), whereas tumors showed a lower expression of PTEN than normal renal tissues.30 Another report among 133 mRCC samples found significantly higher immunoreactivity scores for PI3K, p-mTOR, p-AKT, and p-70S6K in metastatic lesions compared to non-neoplastic proximal tubular epithelial cells.31

A more recent study investigated genetic alterations of 20 representative PI3K/AKT pathway components in ccRCC, such as PIK3CA amplifications or mutations (5%), PTEN deletions or mutations (5%), or mTOR mutations (6%), reiterating the critical role of the PI3K/AKT pathway in this cancer.12

PI3K/AKT/mTOR pathway is also involved in non-clear cell RCC (nccRCC) development. Activating mutations in MET gene found in type 1 pRCC lead to the activation of the PI3K/AKT pathway, resulting in increased proliferation, invasion, and metastasis.32 Mutations in FH, associated with type 2 pRCC, result in the accumulation of fumarate, which leads to the upregulation of HIF-1α and activation of mTOR pathway through the mechanism described earlier.33 In addition, PTEN is the most frequently mutated or deleted component of the PI3K/AKT pathway in chRCC, as found in the latest large-scale genome-sequencing data from the literature.12

Another mechanism involved in ccRCC development and progression is mediated by mitochondrial autophagy, an adaptive metabolic response required to prevent the increase of reactive oxygen species levels and of cell death in hypoxic condition. Autophagy directly degrades oncogenic proteins to suppress tumorigenesis, as a cellular degradation process, resulting in an oncosuppressive mechanism in ccRCC.34 Whereas HIF-1α promotes mitochondrial autophagy through the expression of BNIP3,34 an inhibition of autophagy results in HIF-2α overexpression, which is known to have an oncogenic role in renal tumorigenesis as a transcriptional factor.34 mTOR is known to be a negative regulator of autophagy,36 and mTOR inhibition has been reported to induce autophagy.37

Eventually, considering that mTOR pathway is often activated, with a large cross talk with VHL/HIF pathway, targeting mTOR appears relevant to the antitumor effect in RCC.

**Everolimus**

Everolimus (RAD001, afinitor; Novartis International AG, Basel, Switzerland) is a derivate of rapamycin which inhibits the mTOR serine/threonine kinase; it differs from temsirolimus because it is not converted to rapamycin in vivo. It binds the intracellular receptor protein FKBP12 with a high affinity to form the FKBP12-everolimus complex, which specifically inhibits mTORC1. The disruption of p-S6K1 and 4EBP1 function, the two main downstream effectors of mTORC1, interferes with mRNA translation of genes involved in cell cycle regulation and cellular response to hypoxia.38

Everolimus has been widely tested as an immunosuppressive agent in renal and cardiac transplant, being well tolerated and effective with daily dosing.39,40 In cancer treatment, the first preclinical data demonstrated dose-dependent antitumor activity with daily and weekly administration schedules of everolimus. Boulay et al analyzed the mTOR effectors 4EBP1 activity with daily and weekly administration schedules of everolimus. They showed that suppression of tumor growth correlated with inhibition of p-S6K1 and reduced 4EBP1 phosphorylation. This same experiment ex vivo demonstrated that 4EBP1 levels detected in PBMCs were unaffected by a suboptimal everolimus dosage, despite transient effects on p-S6K1 activity, suggesting that p-S6K1 is a more sensitive marker of everolimus exposure in PBMCs than 4EBP1, making it a possible good pharmacodynamic biomarker of drug activity.41

**Drug formulation and dosing**

Everolimus is orally administered. Preclinical–clinical modeling studies42 and clinical pharmacodynamic studies43 suggest a daily dose of 10 mg, which achieves consistent inhibition of mTOR signaling. Weekly dose of 70 mg did not show the same level of target inhibition as an equivalent daily dose.42

**Pharmacokinetics**

The peak of everolimus concentration (Cmax) is reached from 1 to 2 hours after daily administration of 5–70 mg under fasting conditions. In healthy subjects, high-fat meals reduced
systemic exposure to everolimus (as measured by area under the curve, AUC) by 22%; light-fat meals reduced AUC by 32%. Everolimus is metabolized in the liver by cytochrome CYP3A4 and P-glycoprotein. Six main metabolites have been detected, but they showed 100 times less activity than parent drug. Data about excretion are available from transplant setting studies, since no specific excretion studies have been undertaken in cancer patients. Eighty percent of the drug is eliminated by feces, whereas 5% is excreted in the urine.

Pharmacokinetics was also investigated in special populations. The average AUC of everolimus in eight subjects with moderate hepatic impairment was double compared to AUC found in eight subjects with normal hepatic function. A 3.6-fold increase in exposure was also observed in patients with severe hepatic impairment, suggesting dose adjustments for patients with hepatic dysfunction. No significant influence of creatinine clearance and age (from 27 to 85 years) was detected in a population pharmacokinetic analysis of 170 patients with advanced solid tumors.44

Clinical efficacy
Core evidence of clinical impact of everolimus in the management of mRCC is summarized. The clinical trials of efficacy of everolimus in ccRCC are shown in Table 1, while clinical trials of efficacy of everolimus in nccRCC are shown in Table 2.

Everolimus after failure of previous treatment lines
The first evidence for the clinical efficacy of sequential therapy with everolimus for patients with metastatic ccRCC was provided by a multicenter, international, placebo-controlled Phase III trial (Renal Cell cancer treatment with Oral RAD001 given Daily [RECORD-1]), the results of which were published in 2008 by Motzer et al. Four hundred and ten patients with mRCC were assigned to receive either everolimus 10 mg daily (n=272) or placebo (n=138) by 2:1 randomization. Of note, all patients had progressed to the previous treatment line within 6 months from the start of therapy with VEGFR-tyrosine kinase inhibitors (TKIs) (sunitinib or sorafenib, or both). Median progression-free survival (mPFS), used as primary end point, was 4.0 and 1.9 months for patients treated with everolimus and placebo, respectively (hazard ratio [HR] 0.33, 95% confidence interval [CI] 0.25–0.43; P<0.001). Survival results were still confounded by the treatment crossover permitted after disease progression; an exploratory OS analysis used rank-preserving structural failure time model to correct this bias, and the corrected OS for the everolimus group was 14.8 vs 10.0 months for the placebo group.40

The subsequent everolimus expanded access program (REACT study) enrolled 1,367 patients progressive to first-line treatment: 40% of them received everolimus after only one prior treatment line (in particular 38.5% of overall patients with a VEGFR-TKI), whereas 60% received the drug after two or more prior lines. SD was achieved in 51.6% of patients; 1.7% obtained partial response, and no complete responses were documented; 23.7% of patients had a progressive disease, and 23% were not evaluable for response.51

Very recently, two comparative head-to-head Phase III trials have been published with the aim to demonstrate the superiority of new agents vs everolimus in patients with advanced ccRCC who received one or two previous TKIs.52,53

The first study (METEOR trial) compared the efficacy of cabozantinib, a TKI targeting VEGFR, MET, and AXL proteins, and everolimus in 658 patients with RCC progressive to VEGFR-TKI therapy; PFS was the primary end point. Among the first 375 patients who underwent randomization, 73% were treated in second-line setting, while 27% in third-line
<table>
<thead>
<tr>
<th>Clinical trial</th>
<th>Arms</th>
<th>Design</th>
<th>Population</th>
<th>n</th>
<th>Median PFS (months)</th>
<th>ORR</th>
<th>Median OS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motzer et al&lt;sup&gt;46&lt;/sup&gt;</td>
<td>Everolimus vs placebo</td>
<td>Phase III randomized</td>
<td>Those with mRCC who progressed after one or more prior TKIs</td>
<td>Overall: 416</td>
<td>Overall: 4.9 (everolimus) vs 1.9 (placebo)</td>
<td>2% (everolimus) vs 0% (placebo)</td>
<td>Overall: 14.8 (everolimus) vs 14.4 (placebo)</td>
</tr>
<tr>
<td>RECORD-1 updated results</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Survival corrected for crossover was 1.9-fold longer with everolimus</td>
</tr>
<tr>
<td>Amato et al&lt;sup&gt;48&lt;/sup&gt;</td>
<td>Everolimus</td>
<td>Phase II</td>
<td>Those with mRCC who received one or no prior therapy</td>
<td>Overall: 41</td>
<td>11.2 (everolimus)</td>
<td>14% (everolimus)</td>
<td>22.1 (everolimus)</td>
</tr>
<tr>
<td>Hainsworth et al&lt;sup&gt;69&lt;/sup&gt;</td>
<td>BEV/EVE in first line vs second line</td>
<td>Phase II randomized</td>
<td>Those with mRCC who had received no prior systemic therapy or had progressed to sunitinib, sorafenib, or both</td>
<td>Overall: 80</td>
<td>9.1 (BEV/EVE in first line)</td>
<td>30% (BEV/EVE in first line)</td>
<td>21.3 (BEV/EVE in first line)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Previously untreated: 50</td>
<td>7.1 (BEV/EVE in second line)</td>
<td>23% (BEV/EVE in second line)</td>
<td>15.5 (BEV/EVE in second line)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Previously treated: 30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motzer et al&lt;sup&gt;63&lt;/sup&gt;</td>
<td>Everolimus → sunitinib vs sunitinib → everolimus</td>
<td>Phase II randomized</td>
<td>Those with mRCC who had received no prior systemic therapy</td>
<td>Overall: 471</td>
<td>PFS 1: 7.9 (everolimus → sunitinib) vs 10.7 (sunitinib → everolimus)</td>
<td>8% (everolimus → sunitinib) vs 27% (sunitinib → everolimus)</td>
<td>22.4 (everolimus → sunitinib) vs 32.0 (sunitinib → everolimus)</td>
</tr>
<tr>
<td>RECORD-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Combined PFS 1+2: 21.1 (everolimus → sunitinib) vs 25.8 (sunitinib → everolimus)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ravaud et al&lt;sup&gt;67&lt;/sup&gt;</td>
<td>EVE/BEV vs IFN/BEV</td>
<td>Phase II randomized</td>
<td>Those with mRCC who had received no prior systemic therapy</td>
<td>Overall: 365</td>
<td>9.3 (EVE/BEV) vs 10.0 (IFN/BEV)</td>
<td>27% (EVE/BEV) vs 28% (IFN/BEV)</td>
<td>27.1 (EVE/BEV) vs 27.1 (IFN/BEV)</td>
</tr>
<tr>
<td>Motzer et al&lt;sup&gt;53&lt;/sup&gt;</td>
<td>Everolimus</td>
<td>Phase II</td>
<td>Those with mRCC who progressed after one prior therapy</td>
<td>Overall: 134</td>
<td>After sunitinib: 58</td>
<td>Overall: 7.8 (everolimus)</td>
<td>23.8 (everolimus)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>After other VEGF therapy: 62</td>
<td>After sunitinib: 7.8 (everolimus)</td>
<td>23.8 (everolimus)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>After cytokines: 14</td>
<td>After other VEGF therapy: 7.8 (everolimus)</td>
<td>23.8 (everolimus)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>After cytokines: 12.9 (everolimus)</td>
<td>21.4 (caboazantinib) vs 16.5 (everolimus)</td>
</tr>
<tr>
<td>Choueiri et al&lt;sup&gt;54&lt;/sup&gt;</td>
<td>Cabozantinib vs everolimus</td>
<td>Phase III randomized</td>
<td>Those with mRCC who progressed after one or more prior TKIs</td>
<td>658</td>
<td>7.4 (caboazantinib) vs 3.9 (everolimus)</td>
<td>17% (caboazantinib) vs 3% (everolimus)</td>
<td></td>
</tr>
<tr>
<td>METEOR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motzer et al&lt;sup&gt;59&lt;/sup&gt;</td>
<td>Lenvatinib plus everolimus vs lenvatinib vs everolimus</td>
<td>Phase II</td>
<td>Those with mRCC who progressed after one prior TKI</td>
<td>151</td>
<td>Lenvatinib plus everolimus: 14.6</td>
<td>Lenvatinib plus everolimus: 43%</td>
<td>Lenvatinib plus everolimus: 25.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lenvatinib alone: 7.4</td>
<td>Lenvatinib alone: 27%</td>
<td>Lenvatinib alone: 18.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Everolimus alone: 5.5</td>
<td>Everolimus alone: 6%</td>
<td>Everolimus alone: 17.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.6 (nivolumab) vs 4.4 (everolimus)</td>
<td>25% (nivolumab) vs 5% (everolimus)</td>
<td>25.0 (nivolumab) vs 19.6 (everolimus)</td>
</tr>
<tr>
<td>Motzer et al&lt;sup&gt;52&lt;/sup&gt;</td>
<td>Nivolumab vs everolimus</td>
<td>Phase III randomized</td>
<td>Those with mRCC who progressed after one or two prior antiangiogenic therapies</td>
<td>Overall: 821</td>
<td>One previous antiangiogenic therapy: 591</td>
<td>Two previous antiangiogenic therapies: 230</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** PFS, progression-free survival; ORR, objective response rate; OS, overall survival; mRCC, metastatic renal cell cancer; TKI, tyrosine kinase inhibitor; BEV/EVE, bevacizumab/everolimus; IFN/BEV, interferon-α/bevacizumab; NE, not estimable.
Everolimus in the management of metastatic RCC

In conclusion, both studies demonstrated an advantage in terms of PFS and/or OS for the comparator with respect to everolimus after failure of previous TKI therapies, affording the change of the clinical practice in the next future.

In the light of these recent studies, the role of everolimus in RCC will be undoubtedly shifted to the third or subsequent treatment lines. Nevertheless, neither retrospective nor prospective data have been yet provided about the best therapeutic option after progression to second-line immune checkpoint blockade. Despite the temptation of simply setting. The obtained results were in favor of cabozantinib: the very recently updated reports of METEOR trial results evidenced a final PFS across all the 658 enrolled patients of 7.4 months for cabozantinib compared to 3.9 months for everolimus (HR 0.51, 95% CI 0.41–0.62; \( P<0.0001 \)) and an improved objective response rate (ORR) of 17% with cabozantinib vs 3% for everolimus \( (P<0.0001) \). Moreover, a highly statistically significant and clinically meaningful increase in OS was demonstrated for patients who received cabozantinib compared to everolimus in a second interim analysis for OS of this pivotal Phase III study, reaching an OS of 21.4 months in the experimental arm vs 16.5 months for everolimus (HR 0.66, 95% CI 0.53–0.83; \( P=0.00026 \)).

Subgroup analyses presented at the American Society of Clinical Oncology 2016 Annual Meeting showed that PFS benefit of cabozantinib was obtained in all subgroups of patients defined by prior number and type of TKIs and by the site of metastases (bone and visceral).

The second study (CheckMate 025) compared nivolumab, a PD-1 immune checkpoint inhibitor, to everolimus in an overall population of 821 patients with advanced ccRCC pretreated with one or two antiangiogenic therapies, with OS as primary end point. Seventy-eight percent of patients were treated in second line, while 22% in third line. Results showed a median overall survival (mOS) improvement in patients who received nivolumab compared to those treated with everolimus (25.0 vs 19.6 months; HR 0.73, 98.5% CI 0.57–0.93; \( P=0.002 \)) with no significant differences in terms of mPFS (4.6 months for nivolumab vs 4.4 months for everolimus; HR 0.88, 95% CI 0.75–1.03; \( P=0.11 \)). This could imply that nivolumab may improve overall responses without obtaining an advantage in terms of PFS compared to everolimus. Of note, the mOS obtained with everolimus was better than expected in comparison with RECORD-1 trial, in which mOS for everolimus was 14.8 months; this could be due to a different selection of patients. Moreover, it is interesting to observe that Motzer et al used the modified Memorial Sloan-Kettering Cancer Center prognostic score with three parameters for stratification, instead of the original five parameters score or the more recently validated International Metastatic Renal Cell Carcinoma Database Consortium model by Heng et al. This particular choice could have influenced the expected results in the different subgroups.

### Table 2: Clinical trials of efficacy of everolimus in nccRCC

<table>
<thead>
<tr>
<th>Clinical trial</th>
<th>Arms</th>
<th>Design</th>
<th>Population Notes</th>
<th>n</th>
<th>PFS (months)</th>
<th>ORR (%)</th>
<th>OS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koh et al74</td>
<td>Everolimus</td>
<td>Phase II</td>
<td>Those with metastatic nccRCC</td>
<td>49</td>
<td>Overall: 5.2</td>
<td>10%</td>
<td>14.0</td>
</tr>
<tr>
<td>Escudier et al75</td>
<td>Everolimus</td>
<td>Phase II</td>
<td>Those with metastatic pRCC who had received no prior systematic therapy</td>
<td>92</td>
<td>In first line: 6.1 (everolimus) vs 4.1 (sunitinib)</td>
<td>9%</td>
<td>Overall: 21.1</td>
</tr>
<tr>
<td>Tannir et al76</td>
<td>Sunitinib vs everolimus</td>
<td>Phase II randomized (crossover at PD)</td>
<td>Those with metastatic pRCC who had received no prior systematic therapy</td>
<td>68</td>
<td>In second line: 1.8 (sunitinib) vs 2.8 (everolimus)</td>
<td>9.5%</td>
<td>Papillary type 1: 28.0</td>
</tr>
<tr>
<td>Armstrong et al77</td>
<td>Everolimus vs sunitinib</td>
<td>Phase II randomized</td>
<td>Those with metastatic pRCC who had received no prior systematic therapy</td>
<td>108</td>
<td>Overall: 5.6 (everolimus) vs 8.3 (sunitinib)</td>
<td>5%</td>
<td>Papillary type 2: 20.3</td>
</tr>
</tbody>
</table>

**Abbreviations:** nccRCC, non-clear cell renal cell cancer; PFS, progression-free survival; ORR, objective response rate; OS, overall survival; pRCC, papillary renal cell carcinoma; PD, progressive disease; chRCC, chromophobe renal cell cancer.
shifting the therapeutic sequence, a careful reflection should be dedicated to the issue of suppressing the immune system with everolimus after treatment with an immunostimulating agent such as nivolumab, considering that the opposite effects of such drugs could potentially be counterproductive both on the patient and on the tumor microenvironment.

Indirect comparisons of everolimus efficacy in second-line setting

In December 2011, Rini et al\(^6\) reported the results of a Phase III trial (AXIS study) comparing two alternative second-line therapies after failure of a single first-line treatment, obtaining an mPFS of 6.7 months with axitinib compared to 4.7 months with sorafenib (HR 0.665, 95% CI 0.544–0.812; one-sided \(P<0.0001\)). These findings raised some questions about the role of everolimus in this context, especially considering the design of the study, in which the sequencing was specifically defined as second line, differently from RECORD-1 study which included also subsequent lines. Furthermore, in the AXIS study, the majority of patients (54%) received first-line sunitinib, which is one of the standards of care in clinical practice,\(^1\) whereas the previous treatments in the RECORD-1 study were disparate.

The lack of data regarding head-to-head comparisons of everolimus with other drugs currently approved in second-line setting (ie, axitinib and sorafenib) for the management of advanced RCC raised the need of more in-depth analysis of the topic.

Two recent meta-analyses with indirect treatment comparisons\(^60,61\) have been published with the aim to compare the outcomes among the new targeted agents for pretreated mRCC. With the limits of cross-trial statistical comparisons, data were inconclusive to demonstrate a significant difference in terms of PFS of everolimus vs axitinib or sorafenib, respectively.

Everolimus in a pure second-line setting: RECORD-4 study

Recently, Motzer et al investigated the clinical efficacy of everolimus in a pure second-line setting. Thus, 134 patients were enrolled in a Phase II prospective trial; 58 patients previously received sunitinib, 62 patients received other VEGFR-TKIs, and 14 patients were previously treated with cytokines. mPFS with everolimus was 5.7, 7.8, and 12.9 months, respectively, for the three cohorts. Overall, 67% of patients achieved SD as their best objective response. These data confirm the benefit in terms of PFS of second-line everolimus in mRCC patients.\(^62\)

Everolimus in first-line setting

A Phase II, non-inferiority, randomized trial explored efficacy and safety of first-line treatment with everolimus followed by second-line sunitinib, compared to the standard sequence with sunitinib followed by everolimus in the setting of mRCC, assessing PFS non-inferiority as primary end point. Four hundred and seventy-one patients were randomized to receive one of the two sequences, and the combined mPFS was 21.1 months for the everolimus–sunitinib vs 25.8 months for the sunitinib–everolimus arm (HR 1.3, 95% CI 0.9–1.7).

Since the primary end point was not met, the trial results supported the standard treatment paradigm of first-line sunitinib followed by everolimus at disease progression.\(^63\)

This standard sequence is also supported by the results of a more recent Phase II trial investigating the efficacy of planned alternation of sunitinib and everolimus as first line in 55 patients affected by mRCC. The study treatment consisted of 6-week subcycles of sunitinib 50 mg once daily for 4 weeks followed by 2-week rest, with a subsequent 6-week subcycle of everolimus 10 mg once daily for 5 weeks followed by 1-week rest, for a total of 12 weeks. The primary end point was the status of being both alive and progression free at month 6, and the high level of efficacy for the schedule was set at a PFS at 6 months \(\geq 84\%\). The primary end point was not met since 29 of the 55 assessable participants (53%, 95% CI 40%–66%) were alive and not progressive at 6 months.\(^64\)

Everolimus in combination therapy

Combination therapy is generally associated with better responses but higher toxicity in medical oncology, and it has also been a challenge for mRCC. The rationale of associating two different agents in the treatment of RCC results from the notion that blocking the VEGF pathway can lead to hypoxia, and inhibiting the mTOR response to hypoxia may block the cellular response to the hypoxic stress.\(^65\) Starting from this premise, a Phase II study was conducted on 50 previously untreated and 30 pretreated patients with mRCC. The patients received bevacizumab, an anti-circulating VEGF antibody, and everolimus as first- and second-line therapy, respectively, and showed an mPFS of 9.1 months for first-line therapy and 7.1 months for second-line therapy.\(^66\)

A subsequent large Phase II trial compared everolimus plus bevacizumab (EVE/BEV) to bevacizumab and interferon-\(\alpha\) in 365 mRCC patients previously untreated (RECORD-2 study). The combination EVE/BEV in first line led to a PFS of 9.3 vs 10.0 months of bevacizumab and interferon-\(\alpha\) (HR 0.91, 95% CI 0.69–1.19; \(P=0.485\)).
ORRs were 27% vs 28%, respectively, demonstrating a similar efficacy for the two combination regimens.67

A Phase III trial comparing the use of the combination EVE/BEV to everolimus alone in second-line setting after failure of sunitinib is currently ongoing (NCT01198158).

The approach of combined strategy blocking both the VEGF and PI3K/AKT/mTOR cascade has been assessed in a Phase I study that investigated the safety and efficacy of everolimus plus pazopanib in refractory solid tumors with molecular alterations in the PI3K/AKT/mTOR pathway, such as PI3K mutation and PTEN loss. The treatment seemed to be well tolerated and demonstrated a certain activity in refractory solid tumors.68

More recently, Motzer et al investigated the use of everolimus in combination with a novel TKI, lenvatinib, in a randomized three-arm Phase II study, restoring hopes on synergistic combination therapy. One hundred and fifty-three enrolled patients progressive to first-line VEGFR-TKI were randomly assigned to receive lenvatinib plus everolimus, single-agent lenvatinib, or single-agent everolimus. The combination therapy significantly prolonged mPFS compared to the single-agent everolimus or lenvatinib (14.6 vs 5.5 and 7.4 months, respectively), and ORR was significantly higher for the combination vs single agent (43% vs 6% and 27% for everolimus and lenvatinib, respectively). Moreover, a trend for the combination advantage was also suggested in terms of OS: mOS was 25.5 months for lenvatinib plus everolimus, 18.4 months for single-agent lenvatinib, 17.5 months for single-agent everolimus (HR 0.55, 95% CI 0.3–1.01; P=0.062 for lenvatinib plus everolimus vs single-agent everolimus; and HR 0.74, 95% CI 0.4–1.36; P=0.3 for lenvatinib plus everolimus vs single-agent lenvatinib). The difference in mOS between patients receiving the combination and those treated with everolimus alone was even higher in the post hoc updated analysis, finally reaching statistical significance (25.5 vs 15.4 months; HR 0.51, 95% CI 0.30–0.88; P=0.024). However, the combination treatment seemed to be more toxic than single-agent everolimus; grade 3–4 (G3–4) serious adverse events (AEs) occurred in 71% of patients who received the combination regimen vs 50% for everolimus alone.69

These promising data suggest that maintaining the suppression of VEGF pathway in synergic combination with the inhibition of a main molecular target such as mTOR could represent a good strategy after progression to the first-line VEGFR TKI, even if Phase III studies are needed to confirm this statement.

An interesting Phase II first-line trial by Broom et al evaluated the effect of everolimus alone compared with everolimus plus zoledronic acid on bone metastases from RCC. The primary outcome measure was uNTX level, a measure of bone resorption and a biomarker of effectiveness of bone-specific therapies. Interestingly, a decrease of uNTX level was seen in all patients treated with everolimus plus zoledronic acid over 12 weeks of therapy but not in the cohort of patients treated with everolimus alone. The reduction in mean uNTX on everolimus plus zoledronic acid compared to everolimus alone was 68.3% (P<0.0001). These results indicate that the addition of zoledronic acid may inhibit tumor-induced osteoclast activity more effectively than everolimus alone. A benefit in PFS was also seen by adding zoledronic acid (7.5 months for everolimus plus zoledronic acid vs 5.4 months for everolimus alone, P=0.009), implying that the addition of bisphosphonates to everolimus in patients with bone metastases from RCC may prolong the tumor control.70

Everolimus in nccRCC

Among nccRCCs, pRCC subtype accounts from 7% to 15% of renal cell cancers. Benefits of mTOR inhibition seem to be greater in pRCC than in clear cell subtype, and this could be explained by the upregulation of HIF and products of target genes noticed in this histologic subtype associated with FH mutations.33 In support to this hypothesis, a large Phase III trial explored the efficacy of temsirolimus, an mTOR inhibitor, in 626 patients with previously untreated poor-prognosis mRCC: in this study, temsirolimus showed a better outcome compared to IFN in patients with non-clear cell histotype (n=73). Of note, patients were not stratified by histology.71 Nevertheless, it is not clear if this apparent benefit could be ascribed to a real efficacy of mTOR inhibitor or rather to a detrimental effect of interferon-α (IFN) in this population.72 Based on these observations, a single-arm Phase II trial with everolimus in nccRCC patients was started. Forty-nine patients were enrolled, and 59.2% had papillary histology. Everolimus was given as first-line (53.1%) or second-line therapy (46.9%); mPFS was 3.7 months for previously untreated patients and 5.3 months for patients who progressed after prior sunitinib or sorafenib. Interestingly, patients with chromophobe histology tended to have longer PFS than those with other nccRCC subtypes (13.1 vs 3.4 months, P=0.084).73

In a post hoc subgroup analysis of metastatic nccRCC patients (n=66) enrolled in the RECORD-3 trial, mPFS was shorter for patients treated with everolimus compared to those treated with sunitinib in first-line setting (5.1 vs 7.2 months; HR 1.5, 95% CI 0.9–2.8).63

The following Phase II RAPTOR trial investigated the activity and safety of everolimus as first-line therapy for metastatic pRCC. The mOS for 92 patients was 21.1 months; the
mOS for papillary types 1 and 2 was 28.0 and 20.3 months, respectively.74

More recently, two Phase II randomized trials were conducted to investigate efficacy of everolimus in first-line setting in patients with nccRCC. The first study (ESPN) compared the efficacy of the sequential therapy everolimus–sunitinib vs sunitinib followed by everolimus in patients with metastatic nccRCC. Primary end point was PFS in first-line therapy. In 68 patients, the mPFS for everolimus was 4.1 months when administered in first line, while it was 2.8 months in second line. The mPFS for first-line sunitinib was 6.1 months, and 1.8 months if given in second line. Since the primary end point was not reached, the trial was closed early. The mOS registered for first-line everolimus (10.5 months) was inferior to the OS for first-line sunitinib; at final analysis, mOS was 16.2 months for sunitinib–everolimus sequence and 14.9 months for everolimus–sunitinib (P=0.18).75

The second study (ASPEN) compared everolimus and sunitinib in previously untreated patients with non-clear cell histology. The results showed an mPFS of 5.6 months for everolimus and 8.3 months for sunitinib (HR 1.41, 80% CI 1.03–1.92; P=0.16); mOS was not statistically different between the two treatment groups and was 13.2 vs 31.5 months, respectively (HR 1.12, 95% CI 10.7–2.1; P=0.60). Of note, crossover at progression of disease was not previously established, even if it occurred in 22% of patients receiving sunitinib and in 18% of patients receiving everolimus. The patients were also stratified according to the histological subtypes, and everolimus seemed to have better activity in chRCC, with an mPFS of 11.4 vs 5.5 months of sunitinib. Contrariwise, sunitinib seemed to be more efficient in patients with papillary histotype (mPFS: 8.1 vs 5.5 months).76 However, these results should be handled with care due to the heterogeneous population, small sample size, and imbalance in patients’ characteristics.72

According to this evidence, everolimus is not recommended as first-line therapy in patients affected by metastatic nccRCC, whereas it finds a place in second-line setting after progression to previous sunitinib.

Predictive biomarkers

The identification of predictive biomarkers for response to mTOR inhibitors and the definition of their possible prognostic value has been a challenge since the advent of these new targeted therapies. Various studies identified the overexpression of phosphorylated proteins, such as p-mTOR, p-AKT, p-70S6K, and p-4EBP1, in patients with RCC.29–31 Moreover, phosphorylated forms of S6RP (p-S6RP) and p-4EBP1 are often employed as an immunohistochemical measure of mTOR activity. A large study on 419 ccRCC patients including all stages of disease demonstrated that the cumulative number of altered biomarkers in mTOR pathway is an independent predictor of the clinical outcome, underlying that examining multiple markers together could improve their potential predictive value for response to targeted therapies with mTOR inhibitors.77

The first investigations were conducted on RCC samples of patients treated with temsirolimus: on 20 samples collected from the renal primary tumor (60%) and from metastatic lesions (40%) before the starting of the treatment, a positive association between p-S6RP expression and clinical response to temsirolimus was found, whereas low expression of p-S6RP correlated with progressive disease.78 After TKI failure in Chinese RCC patients, a Phase Ib trial of everolimus explored the expression of p-AKT, p-mTOR, p-4EBP1, and p-S6RP by immunohistochemistry in paraffin-embedded tumor tissue specimens derived from 18 RCC patients. In this study, patients with the expression of p-mTOR or p-S6RP on the primary tumor had longer mPFS compared to patients with no expression (11.3 vs 3.7 months for p-mTOR, P=0.001; 11.3 vs 3.7 months for p-S6RP, P=0.002); co-expression of these two targets with p-4EBP1 was also associated with a longer PFS. Moreover, none of the patients without expression of p-mTOR or p-S6RP experienced benefits with everolimus. According to the results of this study, it could be supposed that expression status of p-mTOR and p-S6RP (that could imply a hyperactivation of mTOR pathway) may be applied as a potential predictive biomarker for everolimus efficacy in patients with mRCC, and a potential indicator for selection of patients.79 However, these data may have been confounded by a bias, since the detection of p-mTOR and p-S6RP has been assessed on tissue available after nephrectomy at baseline, before TKI treatment, and not just before everolimus therapy.

A more recent study by Knoll et al explored the role of p-S6RP, the major mediator of antitumoral effects exerted by everolimus, in vitro and in a novel ex vivo tissue slice model using fresh vital human RCC tissue, and then incubating the tissue with everolimus. While mTOR and S6RP were expressed in all tested cell lines, and their level was not substantially altered by everolimus, the phosphorylation of S6RP was completely blocked by the drug, due to its inhibitory effect on activation of mTOR pathway. As a next step, the investigators explored the effects of everolimus on proliferation and protein synthesis, silencing the expression of S6RP with a small interfering RNA and subsequently treating RCC cells with the drug. Interestingly, the down-regulation of S6RP completely abolished the everolimus inhibitory effect on protein synthesis and cell proliferation,
suggesting that S6RP is crucial for everolimus activity and may be considered as a predictive biomarker.80

Until now, there is no prospectively validated predictive biomarker to monitor everolimus response or to apply a useful selection of patient candidate to mTOR inhibition; S6RP, a main downstream effector of the cascade, and its phosphorylated form p-S6RP are promising for this role, but their clinical use should be further validated.

Safety
Several class-specific AEs can occur with everolimus treatment, such as hyperglycemia, alterations of lipid metabolism, and nonspecific interstitial pneumonitis. According to the RECORD-1 study, the most relevant clinical AEs of every grade in patients treated with everolimus for mRCC were stomatitis (40%), rash (25%), fatigue (20%), asthenia (18%), diarrhea (17%), anorexia (16%), nausea (15%), and pneumonitis (14%). Of these, stomatitis (3%) and fatigue (3%) were the most common toxicities of G3–4. Other relevant complications included G3–4 infections (3%) and G3–4 pneumonitis (3%). The most frequent laboratory abnormalities of any grade were anemia (91%), hypercholesterolemia (76%), hypertriglyceridemia (71%), and hyperglycemia (50%); lymphopenia (16%), hyperglycemia (12%), and anemia (10%) mostly occurred as G3–4 toxicities. Of note, deaths occurred in 14 patients receiving everolimus (5%) within 28 days of their last dose, and one death was caused by overwhelming Candida sepsis, complicated by acute respiratory failure.46

The same toxicity profile was confirmed in more recent studies. In METEOR and CheckMate 025 trials, the well-known toxicity profile of the molecule was furthermore confirmed. Higher-than-expected toxicity was instead reported for everolimus in the METEOR trial, with G3–4 AEs in 58% of cases: this could be partially explained by the fact that the authors of this study quoted all toxicities among events and not only treatment-related AEs.32,53

mTOR pathway has been implicated in insulin resistance:81 mTOR inhibitors are known to be associated with hyperglycemia because of their effects on inhibition of glucose uptake and insulin synthesis.52 Moreover, inhibition of mTOR interferes with cell metabolism, leading to dyslipidemia.21 No official guidelines on the management of hyperglycemia and hyperlipidemia associated with everolimus are available, but physicians should consider an adequate glucose and lipids control before initiation of the treatment, intermittent monitoring of fasting glucose levels, and a strict control of laboratory parameters.83 Some HMG-CoA reductase inhibitors can also be coadministered with everolimus for the treatment of hyperlipidemia, with no significant pharmacokinetic interferences.84

It is important to consider that interstitial pneumonitis also represents a noteworthy complication that can lead to differential diagnosis troubles. It is often asymptomatic, or it could appear with dyspnea and/or cough as a late complication. This AE has been investigated in a substudy of the RECORD-1 pivotal trial: among 274 patients enrolled to receive everolimus, 20 cases required dose reduction due to pneumonitis, and ten permanently discontinued treatment, whereas 54% of clinical pneumonitis (20/37) cases were reversible. Based on radiological features and clinical implications, the authors issued guidelines for specific management of this particular AE.85

Quality of life
Changes in patient’s quality of life (QoL) with everolimus treatment have been investigated in the RECORD-1 Phase III trial. QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire46 and with the Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms;87 both questionnaires were administered before and after treatment with everolimus or placebo. In the study, a trend towards a detrimental effect on physical functioning or global QoL for everolimus arm was evidenced.88

Cost-effectiveness
Cost-effectiveness analysis (CEA) for everolimus has been performed to better understand the budget impact of this targeted drug: outputs were expressed as incremental cost-effectiveness ratio (ICER) and cost per quality-adjusted life-year (QALY). CEA was assessed in the UK after the introduction of everolimus for the treatment of mRCC and was compared to the best supportive care (BSC) alone for the treatment of mRCC in second line: the new targeted drug was not found to be cost-effective compared to BSC, with a base-case ICER of £61,330 and an estimated ICER of £76,070/QALY for everolimus vs BSC. The gain in QALYs was estimated to be 0.304 (0.607 QALYs for BSC plus everolimus vs 0.302 QALYs for BSC plus placebo).89 A subsequent CEA conducted in the US examined the cost-effectiveness of everolimus vs sorafenib in mRCC patients after prior sunitinib failure, and found that everolimus is likely to be cost-effective when compared to sorafenib treatment in this setting of patients (ICER: $89,160/QALY), with a gain in QALYs over sorafenib of 0.916.89 Mihajlović et al conducted a CEA in Serbia, comparing everolimus treatment to BSC in patients refractory to sunitinib, and estimated an ICER of
€87,000/QALY. Based on this analysis, everolimus seemed to be a costly therapeutic alternative to BSC in Serbia but with a relatively small budgetary impact.91

After the advent of axitinib for the treatment of mRCC patients in second-line setting, a CEA was performed on results of two indirect comparisons of outcomes of everolimus vs axitinib from a US payer’s perspective.55,56 Patients treated with everolimus reached an average lifetime cost of $104,226 vs $117,211 for patients treated with axitinib, with a difference of $12,985 in favor of everolimus, largely due to the difference in drug costs. Following sensitivity analyses consistently demonstrated that everolimus remains a less costly therapeutic option than axitinib for treating patients with advanced RCC after failure of standard sunitinib.93

Finally, a recent review dealing with pharancomeconomic and clinical implications of sequential therapy for mRCC patients in Central and Eastern Europe examined availability and reimbursement of drugs for treatment of mRCC up to 2016, showing large access within all Central and Eastern European countries to the standard second-line drugs, including everolimus, despite various restrictions on reimbursement, including those based on duration and choice of previous treatment, for example, in Bosnia and Herzegovina, Latvia, and Serbia.84

**Conclusion**

Everolimus still represents the current standard of treatment for RCC progressive to previous treatment lines with VEGFR-TKI. Its efficacy is maintained independently from the histology, both in clear cell and non-clear cell carcinoma; among ccRCCs, it seems to have a stronger activity on chRCC. Its use in first-line setting, alone or in combination with bevacizumab, is not supported by clinical trials. On the basis of recent evidence, everolimus efficacy could be predicted by immunohistochemical measurements of S6RP and its phosphorylated form, as positive predictive biomarkers of response. The safety of everolimus is widely demonstrated, with an acceptable rate of AEs.

The evidence about two new molecules, cabozantinib and nivolumab, successfully tested head-to-head with everolimus in recently published Phase III trials, will determine the shift of the drug to the third-line setting and subsequent lines of treatment. Promising data for its association with lenvatinib probably support the opportunity of everolimus to still remain in second-line setting for RCC treatment.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


